| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Sep―30 |
19F qNMR based pharmacokinetics, metabolism and mass balance studies of SARS-CoV-2-3CL protease inhibitor simnotrelvir (SIM0417) in humans |
Ze-yu Wang, Yong-mei Ren, Shu-wei Hu, Nai-xia Zhang, Meng-xiao Dong, Yun Li, Yang Yang, Zi-jia Guo, Shan-sen Xu, Jia Chen, Aik Han Goh, Xiao-yan Chen |
| 2 |
[GO] |
2024―Sep―09 |
Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms |
Eileen Chen, Lei Xi |
| 3 |
[GO] |
2023―Mar―21 |
Ceftazidime exhibits a broad inhibition to the infection of SARS-CoV-2 prototype and Omicron variant in vitro by blocking spike protein-ACE2 interaction |
Yun-zhe Zheng, Zhao-yuan Liu, Yue Li, Xiao-ying Lv, Yi Wu, Meng-wen Huang, Xing-chao Pan, Jian-feng Chen, Chang-dong Lin |
| 4 |
[GO] |
2023―Jan―27 |
Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails |
Hang Ma, Hui-fang Zong, Jun-jun Liu, Ya-li Yue, Yong Ke, Yun-ji Liao, Hao-neng Tang, Lei Wang, Shu-sheng Wang, Yun-sheng Yuan, Ming-yuan Wu, Yan-lin Bian, Bao-hong Zhang, Hai-yang Yin, Hua Jiang, Tao Sun, Lei Han, Yue-qing Xie, Jian-wei Zhu |
| 5 |
[GO] |
2022―Oct―17 |
Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies |
Suo-wen Xu, Iqra Ilyas, Jian-ping Weng |
| 6 |
[GO] |
2022―Aug―10 |
Author Correction: Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376 |
Xiao-dong Luan, Bin-xian Chen, Wei-juan Shang, Wan-chao Yin, Ye Jin, Lei-ke Zhang, H. Eric Xu, Shu-yang Zhang |
| 7 |
[GO] |
2022―Jun―30 |
Structure basis for inhibition of SARS-CoV-2 by the feline drug GC376 |
Xiao-dong Luan, Bin-xian Chen, Wei-juan Shang, Wan-chao Yin, Ye Jin, Lei-ke Zhang, H. Eric Xu, Shu-yang Zhang |
| 8 |
[GO] |
2022―Mar―16 |
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects |
Hong-jie Qian, Yu Wang, Meng-qi Zhang, Yuan-chao Xie, Qing-qing Wu, Li-yu Liang, Ye Cao, Hua-qing Duan, Guang-hui Tian, Juan Ma, Zhuo-bing Zhang, Ning Li, Jing-ying Jia, Jing Zhang, Haji Akber Aisa, Jing-shan Shen, Chen Yu, Hua-liang Jiang, Wen-hong Zhang, Zhen Wang, Gang-yi Liu |
| 9 |
[GO] |
2022―Feb―03 |
Author Correction: SARS-CoV-2 receptor binding domain radio-probe: a noninvasive approach for angiotensin-converting enzyme 2 mapping in mice |
Dan Li, Jin Ding, Te-li Liu, Feng Wang, Xiang-xi Meng, Song Liu, Zhi Yang, Hua Zhu |
| 10 |
[GO] |
2022―Jan―20 |
Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
Can-rong Wu, Wan-chao Yin, Yi Jiang, H. Eric Xu |
| 11 |
[GO] |
2021―Dec―10 |
Fibrinolytic therapy for COVID-19: a review of case series |
Hong-Long Ji, Yuling Dai, Runzhen Zhao |
| 12 |
[GO] |
2021―Nov―23 |
SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice |
Dan Li, Jin Ding, Te-li Liu, Feng Wang, Xiang-xi Meng, Song Liu, Zhi Yang, Hua Zhu |
| 13 |
[GO] |
2021―Aug―04 |
Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein |
Lin Wang, Yan Wu, Sheng Yao, Huan Ge, Ya Zhu, Kun Chen, Wen-zhang Chen, Yi Zhang, Wei Zhu, Hong-yang Wang, Yu Guo, Pei-xiang Ma, Peng-xuan Ren, Xiang-lei Zhang, Hui-qiong Li, Mohammad A. Ali, Wen-qing Xu, Hua-liang Jiang, Lei-ke Zhang, Li-li Zhu, Yang Ye, Wei-juan Shang, Fang Bai |
| 14 |
[GO] |
2021―Jul―22 |
Discovery of SARS-CoV-2-E channel inhibitors as antiviral candidates |
Yi Wang, Sui Fang, Yan Wu, Xi Cheng, Lei-ke Zhang, Xu-rui Shen, Shuang-qu Li, Jian-rong Xu, Wei-juan Shang, Zhao-bing Gao, Bing-qing Xia |
| 15 |
[GO] |
2021―Jul―15 |
Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation |
Wei Wang, Sha-sha Li, Xin-feng Xu, Chan Yang, Xiao-ge Niu, Shu-xian Yin, Xiao-yan Pan, Wei Xu, Guo-dong Hu, Chan Wang, Shu-wen Liu |
| 16 |
[GO] |
2021―Apr―13 |
The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective |
Hua-li Zuo, Yang-Chi-Dung Lin, Hsi-Yuan Huang, Xu Wang, Yun Tang, Yuan-jia Hu, Xiang-jun Kong, Qian-jun Chen, Yu-zhu Zhang, Hsiao-Chin Hong, Jing Li, Si-yao Hu, Hsien-Da Huang |
| 17 |
[GO] |
2021―Mar―19 |
Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China |
Xue-qing Liu, Shan Xue, Jia-bo Xu, Heng Ge, Qing Mao, Xin-hui Xu, Han-dong Jiang |
| 18 |
[GO] |
2021―Jan―29 |
Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography |
Rui Li, Hong Wang, Fei Ma, Guang-lin Cui, Li-yuan Peng, Chen-ze Li, He-song Zeng, Ali J. Marian, Dao-wen Wang |
| 19 |
[GO] |
2020―Nov―13 |
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention |
Hai Zou, Sheng-qing Li |
| 20 |
[GO] |
2020―Oct―28 |
Identification of SARS-CoV-2 entry inhibitors among already approved drugs |
Li Yang, Rong-juan Pei, Heng Li, Xin-na Ma, Yu Zhou, Feng-hua Zhu, Pei-lan He, Wei Tang, Ye-cheng Zhang, Jin Xiong, Shu-qi Xiao, Xian-kun Tong, Bo Zhang, Jian-ping Zuo |
| 21 |
[GO] |
2020―Oct―27 |
Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets |
Zoya O. Serebrovska, Elisa Y. Chong, Tetiana V. Serebrovska, Lesia V. Tumanovska, Lei Xi |
| 22 |
[GO] |
2020―Sep―23 |
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives |
Xiao-lei Zhang, Zhuo-ming Li, Jian-tao Ye, Jing Lu, Lingyu Linda Ye, Chun-xiang Zhang, Pei-qing Liu, Dayue D Duan |
| 23 |
[GO] |
2020―Sep―18 |
Author Correction: Cobrotoxin could be an effective therapeutic for COVID-19 |
Fang Lin, Paul F. Reid, Zheng-hong Qin |
| 24 |
[GO] |
2020―Aug―25 |
Cobrotoxin could be an effective therapeutic for COVID-19 |
Fang Lin, Paul F. Reid, Zheng-hong Qin |
| 25 |
[GO] |
2020―Aug―03 |
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 |
Yuan Huang, Chan Yang, Xin-feng Xu, Wei Xu, Shu-wen Liu |
| 26 |
[GO] |
2020―Jun―24 |
Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication |
Xiaocong Pang, Yimin Cui, Yizhun Zhu |
| 27 |
[GO] |
2020―Jun―17 |
Overview of therapeutic drug research for COVID-19 in China |
Heng Li, Li Yang, Fei-fei Liu, Xin-na Ma, Pei-lan He, Wei Tang, Xian-kun Tong, Jian-ping Zuo |
|
